D. Attachment 1 - Purchase Description.pdf

Purchase Description

Name of Item or Project Title:

Compound library of 39 compounds: for the National Center for Advancing Translational Sciences (NCATS) Pharmaceutical Collection (NPC) library update. This is a COVID-19 related activity.

Statement of Need and Purpose:

NCATS is in need of purchasing new drugs approved at 2022 to keep NCATS Pharmaceutical Collection (NPC) library updated to possibly identify new therapeutics for COVID-19

Background Information and Objective:

The NCATS Pharmaceutical Collection (NPC) is a comprehensive, publicly accessible collection of approved and investigational molecular entities for high-throughput screening that provides a valuable resource for both validating new models of disease and better understanding the molecular basis of diseases and interventions. The NPC is composed of a collection of drugs that are approved for human or animal use and drugs that have been in clinical trials. The NPC library is constantly screened at NCATS to identify drugs that can potentially be repurposed for new diseases that are beyond their original indications.

Moreover, the National Center for Advancing Translational Sciences (NCATS) is screening approved drug and mechanistically annotated libraries to identify new therapeutics for COVID-

19. However, the NCATS Pharmaceutical Collection (NPC) drug library is not updated. Thus, the recently approved drugs (2022) shall be acquired to update the NPC library in order to allow NPC to screen the updated library and possibly identify new therapeutics for COVID-19.

Generic Name of Product:

Compound library of 39 compounds

Purchase Description:

The compound library is separated into immediate delivery and later delivery, as described below:

Product_Names CAS Quantity Alflutinib 1869057-83-9 100mg Almonertinib 1899921-05-1 100mg Apatinib 1218779-75-9 100mg Carotegrast methyl 401905-67-7 100mg Chiglitazar 743438-45-1 100mg Coblopasvir 1312608-46-0 100mg Dalpiciclib 1637781-04-4 100mg Danoprevir 850876-88-9 100mg Dorzagliatin 1191995-00-2 100mg Ensartinib 1370651-20-9 100mg Flumatinib 895519-90-1 100mg

Fluzoparib 1358715-18-0 100mg Fruquintinib 1194506-26-7 100mg Futibatinib 1448169-71-8 100mg Icotinib 610798-31-7 100mg Imrecoxib 395683-14-4 100mg Linperlisib 1702816-75-8 100mg Morinidazole 92478-27-8 100mg Olutasidenib 1887014-12-1 100mg Olverembatinib 1257628-77-5 100mg Omidenepag 1187451-41-7 100mg Orelabrutinib 1655504-04-3 100mg Oteseconazole 1340593-59-0 100mg Pacritinib 937272-79-2 100mg Pamiparib 1446261-44-4 100mg Pimitespib 1260533-36-5 100mg Rezvilutamide 1572045-62-5 100mg Tapinarof/Benvitimod 79338-84-4 100mg Contezolid 1112968-42-9 50mg Allisartan isoproxil 947331-05-7 50mg Darinaparsin 69819-86-9 100mg Ciprofol 1637741-58-2

100mg

Ensitrelvir fumaric acid 2757470-18-9 100mg Gefapixant citrate 2310299-91-1

100mg

Surufatinib 1308672-74-3 100mg

Tegoprazan 942195-55-3 100mg

Ansofaxine (Toludesvenlafaxine) 916918-80-4

100mg

Valemetostat tosylate 1809336-93-3 100mg Savolitinib (Volitinib) 1313725-88-0 100mg

Salient Characteristics:

The salient characteristics of the brand-name or equal compound library include:

Each compound must be provided at 50mg/100mg quantity per the above table.

Each compound should be provided with a confirmed purity equal or higher than 95%

(≥ 95);

o In case of nonavailability, vendors may provide quotations with lower compound purity. Compounds with less than 90% (<90) purity shall not be considered.

The compounds shall be delivered no later than 10 weeks;

Certificate of Analysis and Standard Operating Procedure;

The compounds must be replenishable. They must be available for resupply or resynthesis if needed for NCATS follow up in the future; and

Packing and Shipping as described on this Purchase Description.

Quantity:

See above table.

Delivery Date:

Delivery is required within ten (10) weeks after receipt of vials supplied by NCATS.

Packing and Shipping:

Vendor shall provide neat compound dispensed into NCATS provided barcoded, tared vials and report the weight to 0.1mg per vial.

The contractor must also provide the following information electronically for each individual compound. This information must be provided via email referencing individual compound vial barcodes:

Name;

Catalog Number;

Amount;

CAS;

Vial barcode; and Chemical structure or simplified molecular-input line-entry system (SMILES);